|
|
Post by JHam on Sept 2, 2015 10:18:50 GMT
|
|
|
|
Post by JHam on Sept 2, 2015 10:19:14 GMT
- First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST .
- Rodman & Renshaw 17th Annual Global Investment Conference on September 9 at 10:00 AM ET
- Second Annual Global Summit on Practical and Emerging Trends in Melanoma on September 19 starting at 11:15 AM PT
- European Cancer Congress on September 27 at 6:15 PM CEST
- Sachs 15th Annual Biotech in Europe Forum on September 30 at 11:30 AM CEST
|
|
|
|
Post by JHam on Sept 2, 2015 10:20:14 GMT
Here is the big one: European Cancer Congress 2015
Shailender Bhatia, MD, from the University of Washington School of Medicine and principal investigator for OncoSec's Phase II Merkel cell carcinoma trial, will present final results from this study in an oral presentation entitled: "Intratumoral Delivery of Interleukin-12 DNA via In Vivo Electroporation Leads to Regression of Injected and Non-injected Tumors in Merkel Cell Carcinoma: Final Results of a Phase II Study" at the European Cancer Congress on September 27 at 6:15 PM CEST at the Messe Wien Exhibition & Congress Centre in Vienna, Austria. The European Cancer Congress (ECC2015) is a biennial meeting, which combines the efforts of oncology professionals with the aim of improving the prevention, diagnosis, treatment, and care of cancer patients. It is the largest European platform for presenting groundbreaking data to a global audience and the ideal environment for participants to leverage knowledge, promote education, and build awareness about oncology. For more information, please visit: www.europeancancercongress.org/. |
|
|
|
Post by jckrdu on Sept 2, 2015 12:42:36 GMT
- First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST . - Rodman & Renshaw 17th Annual Global Investment Conference on September 9 at 10:00 AM ET - Second Annual Global Summit on Practical and Emerging Trends in Melanoma on September 19 starting at 11:15 AM PT - European Cancer Congress on September 27 at 6:15 PM CEST - Sachs 15th Annual Biotech in Europe Forum on September 30 at 11:30 AM CEST Looks like September 9th is when we'll be getting more information on their new device to treat all types of tumors...
First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."
Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."
|
|
|
|
Post by RLC on Sept 2, 2015 13:03:40 GMT
- First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST . - Rodman & Renshaw 17th Annual Global Investment Conference on September 9 at 10:00 AM ET - Second Annual Global Summit on Practical and Emerging Trends in Melanoma on September 19 starting at 11:15 AM PT - European Cancer Congress on September 27 at 6:15 PM CEST - Sachs 15th Annual Biotech in Europe Forum on September 30 at 11:30 AM CEST Looks like September 9th is when we'll be getting more information on their new device to treat all types of tumors...
First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."
Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."
Great catch Jim! I'm excited to hear about this new device! Hopefully ONCS PPS starts to build in anticipation of the final MCC data and the revealing of the new device. At only a $70 million MC, you'd think more investors would be placing a bet here... |
|
|
|
Post by jckrdu on Sept 2, 2015 13:16:32 GMT
Looks like September 9th is when we'll be getting more information on their new device to treat all types of tumors...
First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."
Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."
Great catch Jim! I'm excited to hear about this new device! Hopefully ONCS PPS starts to build in anticipation of the final MCC data and the revealing of the new device. At only a $70 million MC, you'd think more investors would be placing a bet here... Hey RLC - Agree on the pps building.
Market cap at $85 million with 14.8 million shares issued.
|
|
|
|
Post by RLC on Sept 2, 2015 15:09:36 GMT
Great catch Jim! I'm excited to hear about this new device! Hopefully ONCS PPS starts to build in anticipation of the final MCC data and the revealing of the new device. At only a $70 million MC, you'd think more investors would be placing a bet here... Hey RLC - Agree on the pps building.
Market cap at $85 million with 14.8 million shares issued.
My bad on posting the wrong MC. E*trade needs to update it's info!! |
|
|
|
Post by JHam on Sept 3, 2015 1:31:38 GMT
- First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST . - Rodman & Renshaw 17th Annual Global Investment Conference on September 9 at 10:00 AM ET - Second Annual Global Summit on Practical and Emerging Trends in Melanoma on September 19 starting at 11:15 AM PT - European Cancer Congress on September 27 at 6:15 PM CEST - Sachs 15th Annual Biotech in Europe Forum on September 30 at 11:30 AM CEST Looks like September 9th is when we'll be getting more information on their new device to treat all types of tumors...
First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."
Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."
PD mentioned that the new device would be able to reach virtually any part of the body. If it is going to be an internal catheter device then it looks like that would be true. Very interested to see how this device will be able to zap the site of the tumor and inject IL-12 at the same time. Or will they inject IL-12 they way they have traditionally done with a long needle or something? |
|
|
|
Post by RLC on Sept 3, 2015 4:21:46 GMT
Looks like September 9th is when we'll be getting more information on their new device to treat all types of tumors...
First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."
Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."
Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."
PD mentioned that the new device would be able to reach virtually any part of the body. If it is going to be an internal catheter device then it looks like that would be true. Very interested to see how this device will be able to zap the site of the tumor and inject IL-12 at the same time. Or will they inject IL-12 they way they have traditionally done with a long needle or something? I'm pretty sure the current procedure is an injection of IL-12 by needle, followed by the electroporation using a different device. My assumption is that they will continue to inject IL-12 by needle and the new device is really just a more advanced, miniaturized electroporation device. I'd imagine this could significantly improve patient outcomes of many patients as they'll be able to treat deeper, hard-to-reach cancers (especially cancers that have spread). I had a gut feeling that the PPS would tread lower today, but it was nice to see it hold on good volume. I wouldn't be surprised if we retested the low $5's before seeing a push higher into the final MCC data release (9/27). Although with the conferences kicking off on the 9th, ONCS seemingly receiving increased institutional interest, and this crazy market... who knows! |
|
|
|
Post by JHam on Sept 3, 2015 6:59:18 GMT
PD mentioned that the new device would be able to reach virtually any part of the body. If it is going to be an internal catheter device then it looks like that would be true. Very interested to see how this device will be able to zap the site of the tumor and inject IL-12 at the same time. Or will they inject IL-12 they way they have traditionally done with a long needle or something? I'm pretty sure the current procedure is an injection of IL-12 by needle, followed by the electroporation using a different device. My assumption is that they will continue to inject IL-12 by needle and the new device is really just a more advanced, miniaturized electroporation device. I'd imagine this could significantly improve patient outcomes of many patients as they'll be able to treat deeper, hard-to-reach cancers (especially cancers that have spread). I had a gut feeling that the PPS would tread lower today, but it was nice to see it hold on good volume. I wouldn't be surprised if we retested the low $5's before seeing a push higher into the final MCC data release (9/27). Although with the conferences kicking off on the 9th, ONCS seemingly receiving increased institutional interest, and this crazy market... who knows! Yeah sorry, I should have been more clear. What they do now is first inject IL-12 directly into the tumor, then zap it with electroporation. How will they be able to inject IL-12 directly into a tumor that is located say on the lung or pancreas even if the new device can reach it? |
|
|
|
Post by JHam on Sept 3, 2015 7:03:11 GMT
PD mentioned that the new device would be able to reach virtually any part of the body. If it is going to be an internal catheter device then it looks like that would be true. Very interested to see how this device will be able to zap the site of the tumor and inject IL-12 at the same time. Or will they inject IL-12 they way they have traditionally done with a long needle or something? I'm pretty sure the current procedure is an injection of IL-12 by needle, followed by the electroporation using a different device. My assumption is that they will continue to inject IL-12 by needle and the new device is really just a more advanced, miniaturized electroporation device. I'd imagine this could significantly improve patient outcomes of many patients as they'll be able to treat deeper, hard-to-reach cancers (especially cancers that have spread). I had a gut feeling that the PPS would tread lower today, but it was nice to see it hold on good volume. I wouldn't be surprised if we retested the low $5's before seeing a push higher into the final MCC data release (9/27). Although with the conferences kicking off on the 9th, ONCS seemingly receiving increased institutional interest, and this crazy market... who knows! I am pretty psyched to see the MCC data. I just wished they somehow could have PRed positive results before letting the news trickle out via the conference abstract title. Seems like a missed opportunity. According to the clinicaltrials site, the MCC was to have completed and have full data in Sept. 2015. So they are right on schedule. The lymphoma trial is to be completed with data by Dec. 2015. So if we go by the MCC example, we should have lymphoma data in December. |
|
|
|
Post by RLC on Sept 3, 2015 12:17:54 GMT
I'm pretty sure the current procedure is an injection of IL-12 by needle, followed by the electroporation using a different device. My assumption is that they will continue to inject IL-12 by needle and the new device is really just a more advanced, miniaturized electroporation device. I'd imagine this could significantly improve patient outcomes of many patients as they'll be able to treat deeper, hard-to-reach cancers (especially cancers that have spread). I had a gut feeling that the PPS would tread lower today, but it was nice to see it hold on good volume. I wouldn't be surprised if we retested the low $5's before seeing a push higher into the final MCC data release (9/27). Although with the conferences kicking off on the 9th, ONCS seemingly receiving increased institutional interest, and this crazy market... who knows! Yeah sorry, I should have been more clear. What they do now is first inject IL-12 directly into the tumor, then zap it with electroporation. How will they be able to inject IL-12 directly into a tumor that is located say on the lung or pancreas even if the new device can reach it? I know they can do lung biopsies using a needle (my grandmother had this done several times), so I'd think the actual injection of IL-12 could be administered by needle almost anywhere in the body. It seems like the large electroporation applicator was the issue regarding reach. I really wish I had some good clinical experience so I could understand some of these types of things more clearly. If the new catheter device can deliver IL-12 AND provide the electrical pulses, that would be very impressive... |
|
|
|
Post by JHam on Sept 9, 2015 17:29:25 GMT
I'm pretty sure the current procedure is an injection of IL-12 by needle, followed by the electroporation using a different device. My assumption is that they will continue to inject IL-12 by needle and the new device is really just a more advanced, miniaturized electroporation device. I'd imagine this could significantly improve patient outcomes of many patients as they'll be able to treat deeper, hard-to-reach cancers (especially cancers that have spread). I had a gut feeling that the PPS would tread lower today, but it was nice to see it hold on good volume. I wouldn't be surprised if we retested the low $5's before seeing a push higher into the final MCC data release (9/27). Although with the conferences kicking off on the 9th, ONCS seemingly receiving increased institutional interest, and this crazy market... who knows! Yeah sorry, I should have been more clear. What they do now is first inject IL-12 directly into the tumor, then zap it with electroporation. How will they be able to inject IL-12 directly into a tumor that is located say on the lung or pancreas even if the new device can reach it? Well it looks like we have our answer from today's conference: Advancing 'smart' electroporation technology for minimally invasive immunotherapy; Expanding electroporation IP portfolio with additional license from the University of South Florida ir.oncosec.com/press-releases/detail/1838OncoSec's New Catheter Electrode Technology
OncoSec's new catheter-based electrodes are designed to be compatible with standard medical instrumentation, allowing access to deep and visceral tumors, where they are capable of anchoring to and treating the tumor using OncoSec's proprietary technology. These all-in-one devices have the ability to inject a DNA-based agent, while deploying electrodes to perform electroporation in a single procedure. Moreover, these devices have an adjustable needle and electrode penetration depth allowing clinicians to treat tumors of varying dimensions to perform minimally invasive intratumoral immunotherapy. |
|
|
|
Post by furbush87 on Sept 10, 2015 13:54:47 GMT
Yeah sorry, I should have been more clear. What they do now is first inject IL-12 directly into the tumor, then zap it with electroporation. How will they be able to inject IL-12 directly into a tumor that is located say on the lung or pancreas even if the new device can reach it? I know they can do lung biopsies using a needle (my grandmother had this done several times), so I'd think the actual injection of IL-12 could be administered by needle almost anywhere in the body. It seems like the large electroporation applicator was the issue regarding reach. I really wish I had some good clinical experience so I could understand some of these types of things more clearly. If the new catheter device can deliver IL-12 AND provide the electrical pulses, that would be very impressive... You'd be surprised how easy it is to inject drugs into any place in the body. They have been doing it for years. Very few parts of the body offer any real challenge to reaching. |
|
|
|
Post by RLC on Sept 17, 2015 4:07:08 GMT
Yeah sorry, I should have been more clear. What they do now is first inject IL-12 directly into the tumor, then zap it with electroporation. How will they be able to inject IL-12 directly into a tumor that is located say on the lung or pancreas even if the new device can reach it? Well it looks like we have our answer from today's conference: Advancing 'smart' electroporation technology for minimally invasive immunotherapy; Expanding electroporation IP portfolio with additional license from the University of South Florida ir.oncosec.com/press-releases/detail/1838OncoSec's New Catheter Electrode Technology
OncoSec's new catheter-based electrodes are designed to be compatible with standard medical instrumentation, allowing access to deep and visceral tumors, where they are capable of anchoring to and treating the tumor using OncoSec's proprietary technology. These all-in-one devices have the ability to inject a DNA-based agent, while deploying electrodes to perform electroporation in a single procedure. Moreover, these devices have an adjustable needle and electrode penetration depth allowing clinicians to treat tumors of varying dimensions to perform minimally invasive intratumoral immunotherapy.Ya this is great! The therapy can now treat virtually any tumor (not just surface tumors). I can't imagine this was an inexpensive development. IMO, to go forward with this, they must feel very confident in ImmunoPulse's ability to be a viable treatment (considering they already had an applicator for surface tumors). It also shows the company isn't full of sh*t as they followed through on something they guided and discussed with investors (which is a key thing to prove with companies under $100 million MC). |
|
